Drugs / Adjuvanted influenza vaccine
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00735020 | Jun → Aug 2008 | influenza | Novartis Vaccines | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT00522067 | Jun → Jul 2007 | influenza | Novartis Vaccines | Completed | No outcome recorded |
| Phase 2 | NCT00386113 | Oct → Nov 2006 | influenza | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00386698 | Oct → Dec 2006 | influenza | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00377585 | Sep 2006 → Jan 2007 | influenza | GlaxoSmithKline | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT00559975 Comparator | Oct 2007 → May 2008 | influenza | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00519064 Comparator | Nov → Dec 2006 | influenza | Novartis Vaccines | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2013-03-25 | GlaxoSmithKline | Regulatory update: GlaxoSmithKline receives complete response from FDA for candidate pandemic H5N1 adjuvanted influenza vaccine gsk.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Adjuvanted influenza vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00522067 ↗ |
| Modality | Vaccine | “candidate adjuvanted vaccine” NCT00377585 ↗ |
| Route | Intramuscular | “single intramuscular (IM) administration” NCT00559975 ↗ |